Grants for Small businesses - Science and Technology
Explore 1,048 grant opportunities
Application Deadline
Feb 7, 2025
Date Added
Sep 19, 2024
This grant provides financial support to New Jersey companies for hiring Ph.D. candidates and graduates to conduct technological research and foster innovation in the state.
Application Deadline
Jul 30, 2025
Date Added
Jul 18, 2025
This funding opportunity supports institutions and individuals in developing innovative programs and tools to promote research integrity and prevent misconduct in biomedical and behavioral research.
Application Deadline
Aug 26, 2025
Date Added
Aug 27, 2025
This program provides funding for innovative partnerships that help reduce poverty through economic growth in developing countries, focusing on initiatives like infrastructure resilience and women's entrepreneurship.
Application Deadline
Aug 25, 2024
Date Added
Mar 2, 2024
The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative and revolutionary computational approaches that measure the feasibility of technical claims to enable accurate assessments of scientific content. This publication constitutes a Broad Agency Announcement (BAA) as contemplated in Federal Acquisition Regulation (FAR) 6.102(d)(2) and 35.016 and 2 C.F.R. § 200.203. Any resultant award negotiations will follow all pertinent laws and regulations, and any negotiations and/or awards for procurement contracts will use procedures under FAR 15.4, Contract Pricing, as specified in the BAA. The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals in the following areas of interest: feasibility assessment of scientific content and testing and evaluation of feasibility assessment methods. Proposed research should investigate innovative approaches that enable revolutionary advances in science or systems. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice. Multiple awards are anticipated. The amount of resources made available under this BAA will depend on the quality of the proposals received and the availability of funds.
Application Deadline
Jun 9, 2025
Date Added
Dec 12, 2024
This grant provides funding for innovative technologies that enhance the detection and neutralization of underwater threats, targeting researchers and companies specializing in explosive ordnance disposal and underwater robotics.
Application Deadline
Not specified
Date Added
Nov 21, 2023
Grant Opportunity: The Future of America's Alliances Funder: The Charles Koch Foundation Award Details: Funding levels are commensurate with the requirements of the research and the potential for the research to advance an understanding of critical issues. Accepted proposals may also receive support to disseminate the research findings. Eligibility: Organizations of all types across the USA, including nonprofits, startups, researchers, local governments, and small businesses. Other Relevant Information: - Proposals should evaluate areas where U.S. interests converge or diverge from long-established allies and consider challenges in maintaining alliances in different regions. - Projects should study ways to promote burden-sharing and partners' deterrent capabilities. - Research on the long-term future of NATO, unintended consequences of alliances, advantages of different security arrangements, and problems with foreign arms sales is encouraged. - Proposals should assess historical cases of alliance dissolution and explore options for "transatlantic transformation." - A two-to-five page abstract, CV or résumé, and a brief itemized budget are required in the application. - Proposals will be accepted and evaluated on a rolling basis. For more information and to apply, visit: https://charleskochfoundation.tfaforms.net/344037?tfa_13=tfa_1476
Application Deadline
Jun 14, 2025
Date Added
Apr 17, 2025
This funding opportunity provides financial support to small businesses that previously received Phase I SBIR grants from NIST, enabling them to further develop their innovative projects into commercially viable products or services.
Application Deadline
Mar 3, 2025
Date Added
Nov 8, 2024
This funding opportunity supports innovative projects that develop advanced high-voltage direct current technologies to enhance the resilience and sustainability of the U.S. energy grid, targeting domestic entities and collaborations focused on improving power transmission systems.
Application Deadline
May 15, 2024
Date Added
Dec 6, 2023
Grant Opportunity: Short-term Teaching Artist Residency Program (Illinois) The Short-term Teaching Artist Residency Program in Illinois supports elementary schools, community centers, and public libraries in engaging teaching artists for short-term residencies. The program prioritizes advancing equity and access in the arts, particularly for underserved audiences such as BIPOC communities, individuals with disabilities, older adults, and those with limited access to the arts. Eligible applicants can request a minimum of $250 and a maximum of $4,500 to cover 75% of residency costs. Additional percentages can be added under specific conditions. Applicants must be tax-exempt organizations or units of government in Illinois, while the selected artists must be based in Illinois. The application deadline is at least eight weeks before the project start date. For more information, visit Short-term Teaching Artist Residency Program.
Application Deadline
Aug 31, 2024
Date Added
Aug 8, 2024
The City of Wentzville's Facade Improvement Grant Program aims to preserve historic structures and prevent neighborhood deterioration through renovation and restoration efforts. This initiative is a 50-50 matching grant, with individual projects eligible for up to $10,000. While the description does not explicitly state a foundation mission, the program's focus on historic preservation and community revitalization aligns with broader municipal goals of maintaining aesthetic integrity and fostering economic stability within its districts. The program acts as a strategic tool to achieve these city-wide development and preservation objectives. The target beneficiaries of this program are businesses and mixed-use buildings over 30 years old located within the HD-1, HD-2, or HD-3 zoning districts. The impact goals are multifaceted, seeking to boost property development, strengthen both new and existing businesses, and facilitate the rehabilitation and modernization of downtown buildings. By supporting these specific entities, the program intends to create a ripple effect that benefits the entire community through improved infrastructure and a more vibrant commercial landscape. The program's priorities and focuses are clearly articulated: encouraging the preservation of historic structures, preventing general neighborhood deterioration, and promoting renovation and restoration. These priorities are addressed through the specific design of the grants, which require a 50-50 match, indicating a shared investment and commitment to the success of the projects. The emphasis on properties within designated historic and downtown zoning districts underscores the program's strategic focus on areas critical for community identity and economic activity. Expected outcomes include a visible improvement in the physical appearance of buildings within the targeted districts, increased property values, and a more robust local economy driven by strengthened businesses. Measurable results could include the number of facade renovations completed, the total amount of private investment leveraged by the matching grants, and potentially an increase in new business openings or retention rates within the program areas. While a formal "theory of change" is not explicitly stated for the City of Wentzville, the program implicitly operates on the principle that investing in the physical attractiveness and structural integrity of its commercial and historic properties will lead to enhanced community pride, increased economic activity, and sustained neighborhood vitality.
Application Deadline
Not specified
Date Added
Dec 7, 2023
This program provides funding to Massachusetts-based clean technology startups and academic institutions for projects that advance innovations in areas like high performance buildings, clean transportation, offshore wind, and net zero grid technologies.
Application Deadline
Feb 11, 2026
Date Added
Oct 6, 2025
This funding opportunity provides financial support to domestic entities that own or operate coal-fired power plants, enabling them to recommission, modernize, or retrofit their facilities to enhance grid reliability and support energy needs in rural communities.
Application Deadline
Sep 5, 2025
Date Added
Mar 18, 2025
This funding opportunity seeks innovative research proposals from various entities, including businesses and universities, to develop groundbreaking technologies for national security, focusing on areas like novel materials, quantum computing, and artificial intelligence.
Application Deadline
Not specified
Date Added
Nov 18, 2023
This grant provides financial assistance to Maui-based businesses impacted by the recent wildfires, helping them cover essential expenses like rent, utilities, and inventory replacement.
Application Deadline
Aug 26, 2024
Date Added
May 9, 2024
Key aspects of the TSA: Multidisciplinary Collaboration: The success of the project should depend on the unique skills and perspectives of each partner. The application must clearly define the synergistic components that will facilitate and accelerate progress in melanoma in a way that could not be accomplished through independent efforts. The plans for interactions among all PIs and institutions involved must be clearly articulated. Collectively, the members of the research team should represent the appropriate diversity of expertise necessary for addressing the proposed research question. Participating institutions must be willing to resolve potential intellectual and material property issues and remove institutional barriers to achieving high levels of cooperation. The following components of the proposed multidisciplinary collaboration are encouraged but not required: It is strongly encouraged that the research team has a least one investigator, key personnel, or consultant who can provide input on the ultimate utility/applicability (short- or long-term) of the anticipated outcome(s) to the melanoma field and/or patient care. The inclusion of an early-career investigator is encouraged. An early-career investigator is defined as an independent, early-career researcher or physician-scientist within 7 years of receiving their first faculty appointment by the time of the full application deadline. Investigators in mentored positions, (e.g., postdoctoral fellows) are not eligible to be named as a PI on a TSA application. The inclusion of a military and/or U.S. Department of Veterans Affairs (VA) investigator is encouraged. A military or VA investigator is defined as an investigator who is active-duty, active reserve, active duty detailed to agencies outside of the Department of Defense (DOD), civilian DOD investigators, or an investigator at a VA research facility. If included as PI on the research team, the military/VA investigator should have a substantial role in the research and should not be included only for access to active-duty military and/or VA populations. Impact: The application must articulate the impact the proposed work, including basic research, will have on melanoma research and/or patient care. Outcomes from this award are expected to expedite the advancement of promising ideas toward clinical applications and/or improve the current state of the science/technology in the melanoma field. The proposed research must relate to at least one of the FY24 MRP Focus Areas in Section II.A.1. Preliminary Data Required: Applications must include preliminary data to support feasibility of the study. However, these data do not necessarily need to be derived from melanoma studies. Any unpublished, preliminary data presented should originate from the laboratory of at least one of the PIs or other member(s) of the research team.
Application Deadline
Jun 4, 2024
Date Added
Mar 26, 2024
demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the best and brightest in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research.As the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central features of the award are the demonstrated ability of the individual named as the Principal Investigator (PI) in the application to go beyond conventional thinking in their field and the innovative contribution that the PI can make toward ending breast cancer. The application should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award. Individuals from other disciplines who apply novel concepts to breast cancer are encouraged to submit.The PI is encouraged to assemble a research team that will provide the necessary expertise and collaborative efforts toward accomplishing the research goals. The PIs research team must include two or more breast cancer consumer advocates. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role should be independent of their employment, and they may not be employees of any organizations participating in the application. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project. Their role should be focused on providing objective input throughout the research effort and its potential impact for individuals with, or at risk for, breast cancer.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical trials are allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 Era of Hope Scholar Award should not exceed $3.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $5.4M to fund approximately one Era of Hope Scholar Award application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.
Application Deadline
Dec 3, 2024
Date Added
Nov 19, 2024
This funding opportunity provides financial support to small businesses engaged in innovative research and development projects that have the potential for commercialization and significant societal impact.
Application Deadline
Not specified
Date Added
Jul 26, 2023
This funding opportunity provides financial assistance to bioscience start-ups, early-stage businesses, and academic institutions in Connecticut to help accelerate the commercialization of innovative bioscience breakthroughs.
Application Deadline
Sep 17, 2024
Date Added
May 10, 2024
It is the policy of my Administration to advance womens health research, close health disparities, and ensure that the gains we make in research laboratories are translated into real-world clinical benefits for women. It is also the policy of my Administration to ensure that women have access to high-quality, evidence-based health care and to improve health outcomes for women across their lifespans and throughout the country. President Joseph R. Biden, Jr., Executive Order 14120 on Advancing Womens Health Research and Innovation, 18 March 2024.In support of the Presidents Executive Order to advance womens health research, the PRORP is releasing this WHRA funding opportunity. The intent of the FY24 PRORP WHRA is to support research focused on orthopaedic issues faced by women serving in military settings, such as infantry and other physically demanding roles, who have sustained orthopaedic injuries. The overall goal of the WHRA is to address factors that contribute to the health and retention of women in military service. Although use of military populations, datasets, or samples are not required, the application should demonstrate how the proposed research relates to issues faced by women serving in military settings. The proposed research project should also include a well-formulated, testable hypothesis based on sound scientific rationale and logical reasoning.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.The PRORP encourages applications from a spectrum of research areas, including but not limited to translational and clinical research. The PRORP also welcomes qualitative research, population science, and health care services research specifically designed to understand the impact of orthopaedic injuries on female Service Members.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the PRORP WHRAs focus on orthopaedic injuries in women.A key feature of the PRORP WHRA is the relevance to female military and/or Veteran populations following orthopaedic injury. Inclusion of female military and/or Veteran populations is highly encouraged for applications proposing clinical research. Applicants proposing clinical studies in non-military and/or non-Veteran populations must justify the relevance of the proposed research to the military and/or Veteran communities. All applicants should clearly describe how their study design, including recruitment strategies and access to appropriate populations, as applicable, will enable them to meet this intent.Research involving human subjects, human datasets, and human anatomical substances is permitted; however, the WHRA may not be used to conduct clinical trials. Applicants seeking support for a clinical trial should consider the FY24 PRORP Clinical Trial Award (Funding Opportunity Number HT942524PRORPCTA).Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 7, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.Encouraged Department of Defense (DOD) and/or VA Collaboration: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the VA, and other federal government agencies are encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP WHRA should not exceed $1.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $3.0M to fund approximately two WHRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.
Application Deadline
Not specified
Date Added
May 14, 2024
This grant caters to unique and innovative projects that do not fit the conventional frameworks of the other sub-grants but still demonstrate significant economic development merit. Eligible projects may include feasibility studies, engineered drawings, architecture plans, and planning studies. These projects should aim to significantly impact the economic landscape of Goshen County. Deadlines: Applications due first Friday of November, February, May, August


